Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniela A Bota

Showing results (61-70 of 85) with videos related to

Pageof 9
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|July 31, 2012
Glioma big potassium channel expression in human cancers and possible T cell epitopes for their immunotherapyLisheng Ge, Neil T Hoa, Andrew N Cornforth, et al.
Cell Stem Cell|June 3, 2018
CIRM Alpha Stem Cell Clinics: Collaboratively Addressing Regenerative Medicine ChallengesCatriona H M Jamieson, Maria T Millan, Abla A Creasey, et al.
Frontiers in Neurology|May 22, 2020
A Retrospective Interventional Cohort Study to Assess the Safety and Efficacy of Sandostatin LAR for Treatment of Recurrent and/or Refractory MeningiomasMaya Hrachova, Emely Nhi T Nguyen, Beverly D Fu, et al.
Neuro-Oncology Practice|August 7, 2019
Management of low-grade glioma: a systematic review and meta-analysisTimothy J Brown, Daniela A Bota, Martin J van Den Bent, et al.
Bioengineering & Translational Medicine|January 23, 2026
Glioma chemotherapeutic resistance is tied to membrane electrophysiological properties and glycosylationAlan Y L Jiang, Andrew R Yale, J Nicole Hanamoto, et al.
CNS Oncology|August 31, 2018
Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4<sup>+</sup> T-lymphocyte countsDaniela A Bota, Jinah Chung, Manisha Dandekar, et al.
Human Vaccines & Immunotherapeutics|September 12, 2025
Phase 2 trial of personal dendritic cell vaccines in newly diagnosed glioblastoma: 3-year follow-up and correlations with survivalDaniela A Bota, David E Piccioni, Christopher M Duma, et al.
CA: a Cancer Journal for Clinicians|September 30, 2020
Planning for post-pandemic cancer care delivery: Recovery or opportunity for redesign?Pelin Cinar, Richard Bold, Bryn A Bosslet, et al.
Contemporary Clinical Trials|September 1, 2022
A digital approach to asthma self-management in adults: Protocol for a pragmatic randomized controlled trialJordan Silberman, Siavash Sarlati, Bronwyn Harris, et al.
Frontiers in Oncology|July 15, 2022
A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and TemozolomideDaniela A Bota, Thomas H Taylor, Naomi Lomeli, et al.
Pageof 9

Showing results (61-70 of 85) with videos related to

Sort By:
Pageof 9
Journal of Immunology (Baltimore, Md. : 1950)|July 31, 2012
Glioma big potassium channel expression in human cancers and possible T cell epitopes for their immunotherapyLisheng Ge, Neil T Hoa, Andrew N Cornforth, et al.
Cell Stem Cell|June 3, 2018
CIRM Alpha Stem Cell Clinics: Collaboratively Addressing Regenerative Medicine ChallengesCatriona H M Jamieson, Maria T Millan, Abla A Creasey, et al.
Frontiers in Neurology|May 22, 2020
A Retrospective Interventional Cohort Study to Assess the Safety and Efficacy of Sandostatin LAR for Treatment of Recurrent and/or Refractory MeningiomasMaya Hrachova, Emely Nhi T Nguyen, Beverly D Fu, et al.
Neuro-Oncology Practice|August 7, 2019
Management of low-grade glioma: a systematic review and meta-analysisTimothy J Brown, Daniela A Bota, Martin J van Den Bent, et al.
Bioengineering & Translational Medicine|January 23, 2026
Glioma chemotherapeutic resistance is tied to membrane electrophysiological properties and glycosylationAlan Y L Jiang, Andrew R Yale, J Nicole Hanamoto, et al.
CNS Oncology|August 31, 2018
Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4<sup>+</sup> T-lymphocyte countsDaniela A Bota, Jinah Chung, Manisha Dandekar, et al.
Human Vaccines & Immunotherapeutics|September 12, 2025
Phase 2 trial of personal dendritic cell vaccines in newly diagnosed glioblastoma: 3-year follow-up and correlations with survivalDaniela A Bota, David E Piccioni, Christopher M Duma, et al.
CA: a Cancer Journal for Clinicians|September 30, 2020
Planning for post-pandemic cancer care delivery: Recovery or opportunity for redesign?Pelin Cinar, Richard Bold, Bryn A Bosslet, et al.
Contemporary Clinical Trials|September 1, 2022
A digital approach to asthma self-management in adults: Protocol for a pragmatic randomized controlled trialJordan Silberman, Siavash Sarlati, Bronwyn Harris, et al.
Frontiers in Oncology|July 15, 2022
A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and TemozolomideDaniela A Bota, Thomas H Taylor, Naomi Lomeli, et al.
Pageof 9